{"id":53160,"date":"2023-01-20T21:02:13","date_gmt":"2023-01-20T20:02:13","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/"},"modified":"2023-01-20T21:02:13","modified_gmt":"2023-01-20T20:02:13","slug":"adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/","title":{"rendered":"ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324"},"content":{"rendered":"
\n

SAN DIEGO–(BUSINESS WIRE)–ADARx Pharmaceuticals, Inc.<\/a>, a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the dosing of the first cohort in a Phase 1 clinical study of ADX-324 for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disease that causes painful, rapid, and potentially life-threatening swelling attacks.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe are very excited to be advancing our first candidate that utilizes our proprietary PLR\u2122 delivery platform and SPE\u2122 technology into the clinic,” said Zhen Li, President and Chief Executive Officer. “ADX-324 represents an innovative and differentiated approach for the treatment of HAE.\u201d\n<\/p>\n

\n\u201cDosing of our first participants in this trial is a major milestone for ADARx; in addition to its potential best-in-class efficacy, our pre-clinical studies in non-human primates have confirmed the likelihood for a bi-annual, and possibly annual, low volume subcutaneous dose regimen for ADX-324,\u201d said Feriandas Greblikas, Vice President of Clinical Development.\n<\/p>\n

\nADX-324 is a short-interfering RNA (siRNA) designed to reduce the production of PKK, a protein critical to the etiology of HAE. The study is being conducted in Australia as a randomized, placebo-controlled, double-blind, single ascending dose trial in healthy volunteers with an expansion cohort in patients with HAE. The primary objective of the study is to evaluate the safety and tolerability of ADX-324 when administered by subcutaneous injection.\n<\/p>\n

\nMore information can be found here:
\n
Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients – Full Text View – ClinicalTrials.gov<\/a>\n<\/p>\n

\nAbout ADARx<\/b>\n<\/p>\n

\nADARx Pharmaceuticals, Inc.<\/a>, located in San Diego, is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies including its PLR\u2122 (\u201cPreeminent Liver RNA\u201d) platform and SPE\u2122 (\u201cSequence Specific Platform Enhancement\u201d) technology. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated and central nervous system diseases.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nADARx Contact<\/b>
Roselle Corbaley
\n
(877) 232-7974
\n
ir@adarx.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO–(BUSINESS WIRE)–ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the dosing of the first cohort in a Phase 1 clinical study of ADX-324 for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disease that causes painful, rapid, and potentially life-threatening swelling attacks. \u201cWe are very excited … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53160","6":"format-standard","7":"category-industry"},"yoast_head":"\nADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO–(BUSINESS WIRE)–ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the dosing of the first cohort in a Phase 1 clinical study of ADX-324 for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disease that causes painful, rapid, and potentially life-threatening swelling attacks. \u201cWe are very excited ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-20T20:02:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230120005454\/en\/1692021\/21\/ADARX-Logo-Color-Horizontal.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324\",\"datePublished\":\"2023-01-20T20:02:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\\\/\"},\"wordCount\":348,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230120005454\\\/en\\\/1692021\\\/21\\\/ADARX-Logo-Color-Horizontal.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\\\/\",\"name\":\"ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230120005454\\\/en\\\/1692021\\\/21\\\/ADARX-Logo-Color-Horizontal.jpg\",\"datePublished\":\"2023-01-20T20:02:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230120005454\\\/en\\\/1692021\\\/21\\\/ADARX-Logo-Color-Horizontal.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230120005454\\\/en\\\/1692021\\\/21\\\/ADARX-Logo-Color-Horizontal.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/","og_locale":"en_US","og_type":"article","og_title":"ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324 - Pharma Trend","og_description":"SAN DIEGO–(BUSINESS WIRE)–ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the dosing of the first cohort in a Phase 1 clinical study of ADX-324 for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disease that causes painful, rapid, and potentially life-threatening swelling attacks. \u201cWe are very excited ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-20T20:02:13+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230120005454\/en\/1692021\/21\/ADARX-Logo-Color-Horizontal.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324","datePublished":"2023-01-20T20:02:13+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/"},"wordCount":348,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230120005454\/en\/1692021\/21\/ADARX-Logo-Color-Horizontal.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/","url":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/","name":"ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230120005454\/en\/1692021\/21\/ADARX-Logo-Color-Horizontal.jpg","datePublished":"2023-01-20T20:02:13+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230120005454\/en\/1692021\/21\/ADARX-Logo-Color-Horizontal.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230120005454\/en\/1692021\/21\/ADARX-Logo-Color-Horizontal.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53160","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53160"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53160\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53160"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53160"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}